TSPO and multiple sclerosis: Additionally, XBD173 has a long residence time at the TSPO binding site and a previous study with a mouse multiple sclerosis model suggests that repeated administration of a low dose of XBD173 is beneficial in clinical and pathological outcomes as compared to a higher dose [65, 66].